Advanced Biomed annual return on equity
2023
2024
2025
Advanced Biomed Return on Equity (ROE) Growth & History (ADVB)
Advanced Biomed's return on equity was −126.79% for fiscal 2025.
View full Advanced Biomed company overviewAdvanced Biomed annual return on equity history
| Fiscal year | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-06-30 | −126.79% | +60.64 pp |
| 2024 | 2024-06-30 | −187.43% | −31.81 pp |
| 2023 | 2023-06-30 | −155.62% | — |
Advanced Biomed quarterly return on equity
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
Q3.26
| Fiscal quarter | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| Q3 2026 | 2026-03-31 | −5.23% | +53.05 pp |
| Q2 2026 | 2025-12-31 | 109.85% | +189.41 pp |
| Q1 2026 | 2025-09-30 | −11.94% | — |
| Q4 2025 | 2025-06-30 | −18.45% | — |
| Q3 2025 | 2025-03-31 | −58.28% | — |
| Q2 2025 | 2024-12-31 | −79.56% | — |
Advanced Biomed return on equity trends
Between the periods ended 2023-06-30 and 2025-06-30, Advanced Biomed's return on equity increased from −155.62% to −126.79%, a change of +28.84 percentage points. The latest reported quarter, Q3 2026, shows −5.23%.
About the metric
What return on equity (ROE) means
Return on equity (ROE) measures how much net income a company generates relative to shareholders’ equity. It can help evaluate how efficiently equity capital is used, but unusually high or negative values may reflect leverage, losses, or a small equity base.
Calculation and source
How return on equity is calculated
TickerStat calculates ROE as SEC-reported net income divided by average stockholders’ equity at the beginning and end of the fiscal period. Periods with missing or non-positive average equity are omitted. Quarterly ROE uses quarterly net income and is not annualized. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Advanced Biomed source filings ↗